A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis

Rheumatology

Volumn 39, Issue 6, 2000, Pages 655-665

  Emery, P ^a   Breedveld, F C ^b   Lemmel, E M ^c   Kaltwasser, J P ^d   Dawes, P T ^e   Gomor B ^f   Van Den Bosch, F ^g   Nordstrom D ^h   Bjorneboe O ⁱ   Dahl, R ^j   Horslev Petersen K ^k   Rodriguez De La Serna, A ^l   Molloy, M ^m   Tikly, M ⁿ   Oed, C ^o   Rosenburg, R ^o   Loew Friedrich, I ^o  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Staatl Rheumakrankenhaus   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e Staffordshire Rheumatology Centre   (United Kingdom)

^f NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

^h UNIVERSITY OF HELSINKI   (Finland)

ⁱ MARTINA HANSENS HOSPITAL   (Norway)

^j UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^k HVIDOVRE HOSPITAL   (Denmark)

^l Hospital Sant Pau   (Spain)

^m University College Cork and INFANT Centre   (Ireland)

ⁿ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^o SANOFI   (France)

more..

Author keywords

Clinical trial; Folate supplementation; Leflunomide; Methotrexate; Radiographic assessment of disease progression; Rheumatoid arthritis

Indexed keywords

LEFLUNOMIDE; LIVER ENZYME; METHOTREXATE;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEADACHE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MORTALITY; MULTICENTER STUDY; NAUSEA; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 6744262231     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/39.6.655     Document Type: Article

References (21)

1. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989;16:585-91.
2. Plant MJ, Saklatvala J, Borg AA, Jones PW, Dawes PT. Measurement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol 1994;10:1808-13.
3. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713-22.
4. Felson DT, Anderson JJ, Meehan RF. Use of short-term efficacy/toxicity trade-offs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 1992;35:1117-25.
5. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
6. Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydro-genase. Biochemistry 1996;35:1270-3.
7. Ruckemann K, Fairbanks LD, Carrey EA et al. Lefiunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T lymphocytes from healthy humans. J Biol Chem 1998;273:21682-91.
8. Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem 1995; 270:29682-9.
9. Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259-66.
10. Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159:2542-50.
11. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
12. Smolen JS, Breedveld FC, Eberl G et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 1995;38:38-43.
13. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
14. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol 1977;18:481-91.
15. Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994;330:1368-75.
16. Ward MM, Fries JF. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996. J Rheumatol 1998;25:408-16.
17. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992;35:729-35.
18. Weber W, Harnisch L. Use of a population approach to the development of leflunomide: A new disease-modifying drug in the treatment of rheumatoid arthritis. In: Aarons L, Balant LP, Danhof M et al., eds. European cooperation in the field of scientific and technical research. Brussels: European Commission Directorate-General Science, Research and Development, 1997:239-44.
19. Morgan SL, Baggott JE, Vaughn WH et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994;121:833-41.
20. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 1998;1:36-43.
21. Van Ede A, Laan R, Rood M et al. Effect of folic and folinic acid supplementation on toxicity and efficacy of methotrexate in rheumatoid arthritis: A randomized, double-blind, 48-week clinical trial. Arthritis Rheum 1999;42(Suppl.):S380.